This content is machine translated Podiatry support to improve quality of life Patient mobility with a foot wound Podiatrists are therapists who are specially trained in foot and leg therapy and whose area of responsibility extends from preventive, therapeutic and rehabilitative treatment to the fields of dermatology, diabetology,… CME-Test
View Post 18 min This content is machine translated Hidradenitis suppurativa/acne inversa Challenges of outpatient care The disease hidradenitis suppurativa/acne inversa was first mentioned in 1839 with superficial abscesses on the axillary, submammary and perianal regions. To date, the disease has had various names: Perifolliculitis capitis… CME-Test
View Post 4 min This content is machine translated SLE: Early use of biologics? Findings from the “Leeds SLE Inception Cohort” If systemic lupus erythematosus (SLE) cannot be adequately controlled with hydroxychloroquine and cortisone preparations, the use of immunomodulatory or immunosuppressive agents and/or biologics should be considered according to current EULAR…
View Post 4 min This content is machine translated Dermatomyositis Impaired mitochondrial function as a trigger for SI joint upregulation? The autoimmune disease dermatomyositis is one of the collagenoses andis characterized by muscular symptoms and characteristic skin florescences. There are indications that the disease is controlled by type I interferon.…
View Post 7 min This content is machine translated Interview with Prof. Thomas Kündig (USZ) and Prof. Diego Kyburz (USB) “You have to stop treating psoriasis as just a skin disease”. In Switzerland, psoriasis affects about 1 to 3 percent of the population [1]. About one in three psoriasis patients also suffers from psoriatic arthritis (PsA), a chronic inflammatory systemic disease that…
View Post 4 min This content is machine translated "Small Molecules" at AD Current analyses of the pioneer among the JAK-i The first representative of the Janus kinase (JAK) inhibitor class to be approved for atopic dermatitis was baricitinib. In an extensive study program, this selective and reversible inhibitor of JAK-1…
View Post 6 min This content is machine translated Atopic dermatitis and the skin microbiome How does systemic therapy influence dysbiosis? One aim of the multicenter observational study ProRaD is to gain a better understanding of the mechanisms that influence the course of atopic dermatitis (AD). In a sub-project, researchers used…
View Post 7 min This content is machine translated Biologics for AD Interleukin-13 as a target – new long-term data available Now that the range of systemic therapeutics for atopic dermatitis has been expanded and the two monoclonal antibodies dupilumab and tralokinumab as well as three Janus kinase inhibitors have been…
View Post 6 min This content is machine translated Eosinophilic esophagitis (EoE) Th2 inflammation plays a central role EoE is now considered a type 2-mediated immune disease that is often associated with atopic diseases such as atopic dermatitis, asthma and food allergies. In addition to acid blockers (PPI)…
View Post 4 min This content is machine translated TYK2 inhibition in psoriasis What’s new? The JAK-STAT pathway mediates a variety of proinflammatory responses through Janus kinases (JAK)1-3 andtyrosine kinase-2 (TYK2).Deucravacitinib selectively inhibits TYK2 and was shown to be effective and safe in patients with…
View Post 4 min This content is machine translated Rare and genetic skin diseases “Think out of the box” Rare diseases in Switzerland are defined by a prevalence of less than 1:2000**. There are over 1000 recognized rare skin diseases in dermatology. The “RareSkinCH” network connects reference centers and…
